Lucanthone - Spectrum Pharmaceuticals

Drug Profile

Lucanthone - Spectrum Pharmaceuticals

Alternative Names: Lucanthone hydrochloride; Tixantone

Latest Information Update: 16 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Albert Einstein College of Medicine
  • Developer Spectrum Pharmaceuticals; University of Alabama at Birmingham
  • Class Antineoplastics; Antiparasitics; Radiosensitisers; Small molecules; Thioxanthenes; Xanthones
  • Mechanism of Action DNA apurinic apyrimidinic site lyase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain metastases; Breast cancer; Glioblastoma

Most Recent Events

  • 30 Jan 2018 Spectrum Pharmaceuticals withdraws a phase II trial in Brain metastases (Adjunctive treatment) in USA due to pending resolution of study drug issues (PO) (NCT02014545)
  • 10 Aug 2015 The University of Alabama at Birmingham and Spectrum Pharmaceuticals suspend a phase II trial in Brain metastases (Adjunctive treatment) in USA, as the principal investigator left the university (PO) (NCT02014545)
  • 30 Nov 2013 Phase-II clinical trials in Brain metastases in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top